Gastric Bypass, Obesity
Conditions
Keywords
obesity, gastric bypass, metformin, pharmacokinetics, absorption
Brief summary
Background: Gastric bypass is the most commonly performed type of bariatric (obesity) surgery, has dramatically increased in popularity and is now considered to be preferred treatments in severely obese patients that fail non-surgical therapy - particularly in patients with type 2 diabetes. Drug malabsorption is a potential concern post-gastric bypass because intestinal length is reduced. Purpose: The purpose of this controlled, pharmacokinetic study is to determine whether the absorption of a single dose of metformin, the first line drug treatment in patients with type 2 diabetes, is significantly reduced after gastric bypass. Methods: A single dose of standard release metformin 1000 mg will be administered to patients who have undergone gastric bypass and to patients who have not received surgery but are on the wait list (wait-listed controls). Blood sampling and urine sampling will occur in standardized fashion over the ensuing 24 hours to measure and compare the absorption of metformin between study arms. 34 patients total will be recruited. Significance: Following completion of this study, we will better understand how gastric bypass affects metformin absorption. Ultimately, this information will help to ensure that this patient population is receiving optimal doses of this important drug treatment.
Interventions
None listed
Sponsors
University of Alberta
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
Patients living within and around Edmonton that have been referred to the Alberta Health Services Weight Wise Program
Exclusion criteria
1. Undergone or undergoing revision of a previous bariatric procedure 2. Any major post-operative gastrointestinal complications, such as an anastomotic leak, outlet obstruction or persistent vomiting 3. Currently on metformin therapy 4. Any contraindications to metformin therapy such as: 1. allergy to the drug 2. chronic metabolic acidosis 3. history of lactic acidosis 4. liver failure or baseline liver enzymes higher than 3-fold above the upper limit of normal 5. congestive heart failure 6. renal failure (glomerular filtration rate \< 60 ml/min) 7. alcoholism 8. acute illness 9. fatty liver disease 5. Pregnant or nursing 6. Not taking furosemide or nifedipine (both drugs may increase metformin absorption by 15-20%)the day of visit 2. 7. Any other medical, social or geographic condition, which, in the opinion of the investigator would not allow safe completion of the study protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area-under-the-curve of metformin absorption (0-infinity) | cross-sectional |
Secondary
| Measure | Time frame |
|---|---|
| AUC (0-24h) | cross-sectional |
| tmax | cross-sectional |
| cmax | cross-sectional |
| AUC glucose (0-8h) | cross-sectional |
| bioavailability of metformin (urine metformin concentration from 0-infinity) | cross-sectional |
Countries
Canada
Outcome results
None listed